Verrica Pharmaceuticals Inc.

NasdaqGM:VRCA 주식 보고서

시가총액: US$65.3m

Verrica Pharmaceuticals 관리

관리 기준 확인 2/4

Verrica Pharmaceuticals CEO는 Ted White, Dec2017 에 임명되었습니다 의 임기는 6.92 년입니다. 총 연간 보상은 $ 3.50M, 17.1% 로 구성됩니다. 17.1% 급여 및 82.9% 보너스(회사 주식 및 옵션 포함). 는 $ 158.30K 가치에 해당하는 회사 주식의 0.24% 직접 소유합니다. 158.30K. 경영진과 이사회의 평균 재임 기간은 각각 5.1 년과 6.5 년입니다.

주요 정보

Ted White

최고 경영자

US$3.5m

총 보상

CEO 급여 비율17.1%
CEO 임기6.9yrs
CEO 소유권0.2%
경영진 평균 재임 기간5.1yrs
이사회 평균 재임 기간6.5yrs

최근 관리 업데이트

Recent updates

The Price Is Right For Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Even After Diving 49%

Oct 03
The Price Is Right For Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Even After Diving 49%

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Aug 17
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Analysts Are Cutting Their Estimates: Here's What You Need To Know

With A 67% Price Drop For Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) You'll Still Get What You Pay For

Aug 16
With A 67% Price Drop For Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) You'll Still Get What You Pay For

Is Verrica Pharmaceuticals (NASDAQ:VRCA) Using Debt In A Risky Way?

Jul 21
Is Verrica Pharmaceuticals (NASDAQ:VRCA) Using Debt In A Risky Way?

Is Verrica Pharmaceuticals (NASDAQ:VRCA) Using Debt In A Risky Way?

Jan 11
Is Verrica Pharmaceuticals (NASDAQ:VRCA) Using Debt In A Risky Way?

Here's Why We're Not At All Concerned With Verrica Pharmaceuticals' (NASDAQ:VRCA) Cash Burn Situation

Jun 28
Here's Why We're Not At All Concerned With Verrica Pharmaceuticals' (NASDAQ:VRCA) Cash Burn Situation

We're Hopeful That Verrica Pharmaceuticals (NASDAQ:VRCA) Will Use Its Cash Wisely

Feb 05
We're Hopeful That Verrica Pharmaceuticals (NASDAQ:VRCA) Will Use Its Cash Wisely

Vectoring Back In On Verrica Pharmaceuticals

Aug 31

Verrica Pharmaceuticals reports insider buying

Jul 06

Verrica Pharmaceuticals stock slides on proposed share offering

Jun 29

Verrica Pharmaceuticals Should Receive Second CRL Today

May 24

Auditors Have Doubts About Verrica Pharmaceuticals (NASDAQ:VRCA)

Mar 07
Auditors Have Doubts About Verrica Pharmaceuticals (NASDAQ:VRCA)

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Mar 06
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Time To Worry? Analysts Just Downgraded Their Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Outlook

Dec 17
Time To Worry? Analysts Just Downgraded Their Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Outlook

FDA extends review period for Verrica Pharmaceuticals' VP-102 NDA

May 28

Verrica Pharmaceuticals EPS beats by $0.32

May 07

Verrica Pharma refiles US application for lead candidate in infectious skin disease

Dec 23

CEO 보상 분석

Ted White 의 보수는 Verrica Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Jun 30 2024n/an/a

-US$87m

Mar 31 2024n/an/a

-US$81m

Dec 31 2023US$4mUS$601k

-US$67m

Sep 30 2023n/an/a

-US$48m

Jun 30 2023n/an/a

-US$23m

Mar 31 2023n/an/a

-US$23m

Dec 31 2022US$2mUS$572k

-US$24m

Sep 30 2022n/an/a

-US$28m

Jun 30 2022n/an/a

-US$41m

Mar 31 2022n/an/a

-US$43m

Dec 31 2021US$2mUS$550k

-US$35m

Sep 30 2021n/an/a

-US$39m

Jun 30 2021n/an/a

-US$36m

Mar 31 2021n/an/a

-US$34m

Dec 31 2020US$2mUS$485k

-US$43m

Sep 30 2020n/an/a

-US$37m

Jun 30 2020n/an/a

-US$33m

Mar 31 2020n/an/a

-US$31m

Dec 31 2019US$1mUS$433k

-US$28m

Sep 30 2019n/an/a

-US$28m

Jun 30 2019n/an/a

-US$28m

Mar 31 2019n/an/a

-US$26m

Dec 31 2018US$5mUS$400k

-US$21m

Sep 30 2018n/an/a

-US$20m

Jun 30 2018n/an/a

-US$15m

Mar 31 2018n/an/a

-US$11m

Dec 31 2017US$24kUS$24k

-US$10m

보상 대 시장: Ted 의 총 보상 ($USD 3.50M )은 US 시장( $USD 653.78K ).

보상과 수익: 회사가 수익성이 없는 동안 Ted 의 보상이 증가했습니다.

CEO

Ted White (59 yo)

6.9yrs

테뉴어

US$3,504,647

보상

Mr. Ted White has been the President and Chief Executive Officer at Verrica Pharmaceuticals Inc. since December 2017 and has been its Director since May 2018. Mr. White served as the President and General...

리더십 팀

이름위치테뉴어보상소유권
Ted White
President6.9yrsUS$3.50m0.24%
$ 158.3k
Christopher Hayes
Chief Legal Officer6.2yrsUS$2.56m0.15%
$ 100.6k
Gary Goldenberg
Chief Medical Officer4.3yrsUS$989.18k0.13%
$ 83.0k
Eugene Scavola
Executive Vice President of Technical Operations5.1yrs데이터 없음데이터 없음
Bradley Catalone
Head of Drug Development4.3yrs데이터 없음데이터 없음

5.1yrs

평균 재임 기간

59yo

평균 연령

경험이 풍부한 관리: VRCA 의 관리팀은 노련하고 경험 (평균 재직 기간 5.1 년)입니다.

이사회 구성원

이름위치테뉴어보상소유권
Ted White
President6.5yrsUS$3.50m0.24%
$ 158.3k
Mark Prygocki
Independent Director6.5yrsUS$119.19k0%
$ 0
Mark Lebwohl
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Lawrence F. Eichenfield
Independent Director4.3yrsUS$119.19k0%
$ 0
Sean Stalfort
Director8.9yrs데이터 없음1.08%
$ 707.0k
Paul Manning
Chairman of the Board8.9yrs데이터 없음31.75%
$ 20.7m
Steven Cohen
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Elaine Siegfried
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Anthony Mancini
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Janice Pelletier
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Robert Greenberg
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Diem Nguyen
Independent Director4.4yrsUS$99.19k0.00023%
$ 150.2

6.5yrs

평균 재임 기간

58yo

평균 연령

경험이 풍부한 이사회: VRCA 의 이사회는 경험(평균 재직 기간 6.5 년)으로 간주됩니다.